Bristol-Myers Squibb Company (BMY)
Health Care5 articles
Market Mood
SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a year-to-date price return of 20% and currently yields approximately 3.3%. The fund has $71.6 billion in assets and a low expense ratio of 0.06%. Its top holdings include Bristol Myers Squibb, Lockheed Martin, and Chevron, all recognized as Dividend Aristocrats with strong free cash flow. The balanced weighting of positions helps mitigate risks, reinforcing distribution safety despite recent company-specific challenges.
Read More
Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
Bristol Myers Squibb (BMY) announced its partnership with Anthropic to implement the Claude AI model in its drug discovery process. This collaboration aims to enhance efficiency and reduce timelines associated with drug development. The deployment of AI technology exemplifies BMY's commitment to innovation within the pharmaceutical sector. As companies increasingly adopt AI tools, the market could see shifts in research and development dynamics, potentially impacting stock performance.
Read More
Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.
Read More
Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
Bristol-Myers Squibb Company (BMY) ranks 5th among the best defensive stocks and is recognized for low volatility and high yield. The stock features a beta that is approximately 73% less volatile than the S&P 500. Recent updates include a quarterly dividend of $0.63 per share and a cash payout ratio of about 35%. In the recent quarter, growth products like Camzyos and Sotyktu saw a 10% increase, which strengthens BMY's long-term revenue outlook despite some earnings challenges.
Read More
BMY Stock Rating Reiterated at Buy by Guggenheim
Guggenheim has reiterated its 'Buy' rating on Bristol-Myers Squibb (BMY). This endorsement could signal ongoing confidence in the company's stock performance amid its recent market activities. As institutional recommendations often influence investor sentiment, this reaffirmation may encourage additional interest from shareholders. It reflects a strategic outlook towards BMY amidst a competitive biotechnology sector.
Read More